|
FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 180
|
|
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
|
Written by: J. Smith |
Hits: 91
|
|
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
|
Written by: J. Smith |
Hits: 384
|
|
Dexcom Introduces Smart Basal at EASD 2025
|
Written by: J. Smith |
Hits: 343
|
|
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
|
Written by: J. Smith |
Hits: 111
|
|
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
|
Written by: J. Smith |
Hits: 227
|
|
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration
|
Written by: J. Smith |
Hits: 169
|
|
CVS Caremark Faces Lawsuit Over Dropping Zepbound
|
Written by: J. Smith |
Hits: 142
|
|
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
|
Written by: J. Smith |
Hits: 223
|
|
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes
|
Written by: J. Smith |
Hits: 188
|
